SCHEMBL20802113

SCHEMBL20802113

O=c1c(OC[C@@H](OC2OC(CO)C(O)C(O)C2O)C(O)C(O)C(O)CO)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 6/20 0.69
▸ KDM4E B2RXH2 5/20 0.69
▸ AKR1B1 P15121 5/20 0.69
▸ P4HB P07237 5/20 0.69
▸ EPHX2 P34913 5/20 0.69
▸ POLB P06746 4/20 0.69
▸ MAPT P10636 3/20 0.69
▸ CA12 O43570 2/20 0.69
▸ CA2 P00918 2/20 0.69
▸ CA4 P22748 2/20 0.69
▸ CA7 P43166 2/20 0.69
▸ ALPL P05186 2/20 0.69
▸ ALPI P09923 2/20 0.69
▸ ADRA2C P18825 1/20 0.69
▸ NOX4 Q9NPH5 1/20 0.69
▸ KDM1A O60341 1/20 0.69
▸ SLCO2B1 O94956 1/20 0.69
▸ HMGB1 P09429 1/20 0.69
▸ PKM P14618 1/20 0.69
▸ MAOA P21397 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20802175 0.92 EPHX2 (0.71) GAAKDM4EAKR1B1P4HBEPHX2
SCHEMBL20802114 0.91 P4HB (0.66) GAAKDM4EAKR1B1P4HBEPHX2
SCHEMBL20802174 0.90 KDM4E (0.64) GAAKDM4EAKR1B1P4HBEPHX2
SCHEMBL20802116 0.84 P4HB (0.62) GAAKDM4EAKR1B1P4HBEPHX2
SCHEMBL19490598 0.83 POLH (0.70) GAAKDM4EAKR1B1P4HBEPHX2
Isoquercetin SCHEMBL19212904 0.82 P4HB (1.00) GAAKDM4EAKR1B1P4HBEPHX2
Isoquercetin SCHEMBL21244358 0.82 P4HB (1.00) GAAKDM4EAKR1B1P4HBEPHX2
Isoquercetin SCHEMBL9916971 0.82 P4HB (1.00) GAAKDM4EAKR1B1P4HBEPHX2
Isoquercetin SCHEMBL22495101 0.82 P4HB (1.00) GAAKDM4EAKR1B1P4HBEPHX2
Isoquercetin SCHEMBL12566342 0.82 P4HB (1.00) GAAKDM4EAKR1B1P4HBEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10765128-B2 Composition for prevention or treatment of metabolic syndrome or for antioxidation containing black bean leaf extracts and flavonol glysosides isolated therefrom as active ingredients KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2020-09-08 — — US disclosed
US-20190075823-A1 COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC SYNDROME OR FOR ANTIOXIDATION CONTAINING BLACK BEAN LEAF EXTRACTS AND FLAVONOL GLYSOSIDES ISOLATED THEREFROM AS ACTIVE INGREDIENTS KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2019-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10765128-B2 Composition for prevention or treatment of metabolic syndrome or for antioxidation containing black bean leaf extracts and flavonol glysosides isolated therefrom as active ingredients GPX1, GSTP1, GSS GAA 92/4885KDM4E 4058/4885AKR1B1 1199/4885
US-20190075823-A1 COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC SYNDROME OR FOR ANTIOXIDATION CONTAINING BLACK BEAN LEAF EXTRACTS AND FLAVONOL GLYSOSIDES ISOLATED THEREFROM AS ACTIVE INGREDIENTS GPX1, GSTP1, PON1 GAA 144/4885KDM4E 4169/4885AKR1B1 892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback